In conclusion, the assessment of vascular tumour angiogenesis markers in relationship to CTC involvement and the expression of angiogenesis markers in terms of histo-pathological grading, lymph node involvement, hormone receptor status, TNM classification and survived breast cancer patients vs. deceased tumour associated patients, could found an advantage in regard to assessing the discrete risk of patients at the time of primary diagnosis. Here, NR4A1 is linked to breast carcinoma.